Predictive And Presymptomatic Testing Market Set to Reach $8.47 Billion by 2029 with 10.1% Yearly Growth

What industry-specific factors are fueling the growth of the predictive and presymptomatic testing market?
The growing incidence of genetic disorders is likely to fuel the expansion of the predictive and presymptomatic testing market in the future. Genetic disorders, encompassing gene mutations and chromosomal changes, are conditions resulting from deoxyribonucleic acid (DNA) anomalies, such as cystic fibrosis and down syndrome. The escalating incidence of genetic disorders can be ascribed to aspects like older maternal age, environmental influences, and improved diagnostic processes. Predictive and presymptomatic testing is essential in decreasing the occurrence of genetic disorders by pinpointing individuals at risk prior to the appearance of symptoms. This preventive strategy enables early interventions or alterations in lifestyle that can assist in avoiding or lessening the intensity of these disorders. For example, in June 2023, as per the American Society of Gene and Cell Therapy, a nonprofit medical and scientific organization based in the US, there was a 10% growth in the number of gene therapies in Phase III clinical trials in the third quarter of 2023, marking the first rise since the third quarter of 2022. Consequently, the escalating incidence of genetic disorders is spurring the growth of the predictive and presymptomatic testing market.

Get Your Predictive And Presymptomatic Testing Market Report Here:
https://www.thebusinessresearchcompany.com/report/predictive-and-presymptomatic-testing-global-market-report

What Is the projected market size and growth rate for the predictive and presymptomatic testing market?
The market size for predictive and presymptomatic testing has been expanding swiftly in the past few years. It is projected to increase from $5.24 billion in 2024 to $5.78 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. The expansion in the last few years can be accredited to a heightened occurrence of genetic disorders, an increased necessity for early detection of chronic illnesses, a rise in cancer rates, a growing endorsement for personalized medicine, and a broader availability of direct-to-consumer genetic tests.

It is anticipated that the predictive and presymptomatic testing market will experience swift expansion in the upcoming years, reaching a value of $8.47 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 10.1%. The escalation in this timeframe is credited to factors such as the growing need for early detection of diseases, increased funding in biotechnology and genomics, a surge in demand for non-invasive testing strategies, an expanding aged demographic, and advancement in precision medicine initiatives. Noteworthy trends predicted for this period encompass the embrace of personalized medicine and home testing kits, the amalgamation of genomics and big data, the progress of next generation sequencing (NGS) technologies, and the incorporation of predictive testing into drug development processes.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20594&type=smp

What new trends are reshaping the predictive and presymptomatic testing market and its opportunities?
Leading firms in the predictive and presymptomatic testing market are introducing cutting-edge tests like multigene testing. This type of test analyses several genes at one time in order to pinpoint potential health threats and facilitate early preventative measures. Multigene testing is a diagnostic method that simultaneously studies multiple genes to detect genetic mutations or variations linked with specific diseases or conditions, supporting individualized medication and tailored treatment plans. For example, in July 2022, Genetic Technologies Limited, a research company based in Australia, collaborated with Siles Health, a women's healthcare center in Australia, to roll out the geneType Multi-Risk Test. This test offers complete risk assessments for patients. The geneType Multi-Risk Test is an all-inclusive genetic evaluation tool that gauges a patient's risk for several serious diseases, including breast cancer, colorectal cancer, and type 2 diabetes. By studying both inherited and sporadic genetic factors, the test seeks to influence personalized healthcare plans and allow for early preventative measures.

What major market segments define the scope and growth of the predictive and presymptomatic testing market?
The predictive and presymptomatic testing market covered in this report is segmented -

1) By Test Type: Predictive Testing, Presymptomatic Testing
2) By Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Other Applications
3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users

Subsegments:
1) By Predictive Testing: Genetic Testing for Inherited Conditions, Cancer Risk Prediction, Cardiovascular Disease Prediction, Neurodegenerative Disease Risk Prediction, Genetic Screening for Autosomal Dominant Disorders, Prenatal Predictive Testing, Pharmacogenomic Testing
2) By Presymptomatic Testing: Huntington's Disease Testing, Hereditary Cancer Risk Testing, Cystic Fibrosis Presymptomatic Testing, Early-Onset Alzheimer's Disease Testing, Carrier Screening for Genetic Conditions, Testing for Early Signs of Neurodegenerative Diseases, Presymptomatic Genetic Testing for Familial Diseases

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20594

Which region dominates the predictive and presymptomatic testing market?
North America was the largest region in the predictive and presymptomatic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the predictive and presymptomatic testing industry growth?
Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20594&type=smp

What Is Covered In The Predictive And Presymptomatic Testing Global Market Report?

•Market Size Forecast: Examine the predictive and presymptomatic testing market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the predictive and presymptomatic testing market for a structured understanding.
•Key Players Overview: Analyze major players in the predictive and presymptomatic testing market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the predictive and presymptomatic testing market.
•Segment Contributions: Evaluate how different segments drive overall growth in the predictive and presymptomatic testing market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the predictive and presymptomatic testing market.
•Industry Challenges: Identify potential risks and obstacles affecting the predictive and presymptomatic testing market.
•Competitive Landscape: Review strategic developments in the predictive and presymptomatic testing market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.